GlassScriptPhysician profile
Beatriz E Carmona Toro
NPI 1437452885
$13,821.59
in general payments reported to CMS, 2019-2025
58 companies · $2,969 in 2025
The $2,969 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,540 · 2022: $2,448 · 2023: $2,633 · 2024: $3,230 · 2025: $2,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,523 · Education: $160 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,522.98 |
| Education | $159.99 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,718.81 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $1,703.48 | 2021-2025 | Xywav |
| Acadia Pharmaceuticals INC | $727.40 | 2021-2025 | Nuplazid, Daybue |
| Genzyme Corporation | $711.12 | 2021-2025 | |
| Harmony Biosciences LLC | $671.27 | 2023-2025 | Wakix |
| Lilly USA, LLC | $586.67 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Avadel Cns Pharmaceuticals, LLC | $547.04 | 2023-2025 | Lumryz |
| Ucb, INC. | $543.88 | 2021-2025 | Rystiggo, Briviact |
| Amgen INC. | $531.46 | 2021-2025 | Uplizna |
| Biogen, INC. | $455.02 | 2021-2025 | Leqembi, Spinraza |
| Teva Pharmaceuticals USA, INC. | $427.11 | 2021-2023 | Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $410.55 | 2023-2025 | Sunosi, Auvelity |
| Csl Behring | $346.27 | 2021-2025 | Hizentra |
| Horizon Therapeutics Plc | $345.35 | 2021-2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $321.71 | 2021-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatriz Carmona Toro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.